Palliative repeated electroporations of oral tumours in dogs: A case series.
dog
electrochemotherapy
neoplasia
oncology
oral cavity tumour
repeated electroporations
Journal
Frontiers in veterinary science
ISSN: 2297-1769
Titre abrégé: Front Vet Sci
Pays: Switzerland
ID NLM: 101666658
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
07
2022
accepted:
25
10
2022
entrez:
28
11
2022
pubmed:
29
11
2022
medline:
29
11
2022
Statut:
epublish
Résumé
Electrochemotherapy (ECT) is a highly developed treatment for many solid tumours that provides good local control in 80% of neoplasms in dogs. ECT can be used to treat different types of tumours, particularly as an innovative approach for non-resectable masses. As reported in the literature, electroporation-based treatments are safe, simple, fast and cost-effective treatment alternatives for selected oral and maxillofacial tumours not involving the bone in dogs (e.g., small squamous cell carcinoma or malignant melanoma). In this descriptive retrospective paper, the authors describe the outcome of various types of oral tumours treated with ECT as a palliative first line treatment or as a rescue treatment in dogs with local tumour recurrence. Nineteen dogs were included and treated with at least one session of three electroporations coupled with intravenous administration of bleomycin every 21 days. Tumour size, localization, histotype, stage, recurrence, solid tumour response evaluation criteria (RECIST), local toxicity, progression free survival (PFS) and median survival time (MST) were evaluated. The small population did not allow the analysis of the ECT response by comparing different tumour types; further studies with a larger caseload are needed. However, all dogs, despite the low MST, showed a good local response to treatment with a rapid improvement in quality of life from the first ECT application; no side effects attributable to chemotherapy have been detected and toxicity due to the electroporation was minimal and well tolerated in all dogs.
Identifiants
pubmed: 36439338
doi: 10.3389/fvets.2022.1004811
pmc: PMC9685614
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1004811Informations de copyright
Copyright © 2022 Moretti, Dentini, Beccati, Arcelli, Matteo, Giovannini and Bufalari.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Cancer. 2017 Dec;87:172-181
pubmed: 29156298
Cancers (Basel). 2021 Mar 12;13(6):
pubmed: 33809141
Open Vet J. 2019 Apr;9(1):88-93
pubmed: 31086772
Vet Pathol. 1989 Mar;26(2):121-8
pubmed: 2711569
J Am Vet Med Assoc. 1976 Dec 1;169(11):1202-6
pubmed: 1002589
Front Vet Sci. 2020 Sep 29;7:575911
pubmed: 33134356
Vet Comp Oncol. 2020 Sep;18(3):428-432
pubmed: 31419028
Acta Oncol. 2016 Nov;55(11):1266-1272
pubmed: 27705053
Melanoma Res. 2006 Feb;16(1):23-7
pubmed: 16432452
Vet Comp Oncol. 2015 Sep;13(3):176-83
pubmed: 23534501
J Vis Exp. 2016 Oct 24;(116):
pubmed: 27805594
In Vivo. 2009 Jan-Feb;23(1):55-62
pubmed: 19368125
Radiol Oncol. 2020 Mar 7;54(1):68-78
pubmed: 32187017
Vet Comp Oncol. 2017 Sep;15(3):775-784
pubmed: 27001443
Artif Organs. 2018 Mar;42(3):297-304
pubmed: 29027689
Vet Clin North Am Small Anim Pract. 2019 Sep;49(5):967-979
pubmed: 31176458
J Small Anim Pract. 2017 Mar;58(3):146-153
pubmed: 28224623
Vet Comp Oncol. 2019 Sep;17(3):234-241
pubmed: 30688021
Zentralbl Veterinarmed A. 1987 Jun;34(6):420-7
pubmed: 3113126
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437